Telix Pharmaceuticals(TLX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Telix Pharmaceuticals
TLX.US
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer.
1.955 T
TLX.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
B
BiotechnologyIndustry
Industry Ranking26/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.14%C
    • Profit Margin1.63%C
    • Gross Margin48.62%B
  • Growth ScoreB
    • Revenue YoY55.35%A
    • Net Profit YoY-66.76%D
    • Total Assets YoY139.09%A
    • Net Assets YoY56.55%A
  • Cash ScoreA
    • Cash Flow Margin6125.09%A
    • OCF YoY55.35%A
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreD
    • Gearing Ratio64.54%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Telix Pharmaceuticals reports $804 million in full-year revenue, with a 46% increase in Q4 revenue reaching $208 million.

    Telix Pharmaceuticals Limited reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance. The company experienced a 46% year-over-year increase in Q4 revenue, reaching around $208 million. The Precision Medicine segment contributed about $161 million, reflecting a 4% quarter-over-quarter growth. Telix is advancing its clinical studies, including the ProstACT Global Phase 3 and SOLACE Phase 1 trials, and has initiated dosing in the BiPASS Phase 3 trial in the U.S. The stock is currently at lows, potentially testing lower boundaries.

    Unusual Whales·
    US
    TLX
    +4.24%
    Unusual Whales·
    US
    TLX
    +4.24%

    Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

    Telix Pharmaceuticals reported strong FY25 revenue of approximately $804 million, meeting its target with a 46% increase in Q4 revenue. Despite this, the stock is down 56.91% over the past year, trading below key moving averages. Analysts maintain a Buy rating with a target of $21.20, citing potential growth from its shift to a radiopharmaceutical focus. However, the stock's low momentum score indicates ongoing challenges, with shares trading at $7.20, down 6.86% recently.

    benzinga_article·
    US
    TLX
    +4.24%
    benzinga_article·
    US
    TLX
    +4.24%

    Telix Pharmaceuticals (NASDAQ:TLX) Hits New 52-Week Low - Time to Sell?

    Telix Pharmaceuticals (NASDAQ:TLX) shares hit a new 52-week low of $7.26, down from a previous close of $7.73. Analysts have mixed opinions, with Royal Bank of Canada upgrading the stock to 'moderate buy' while Wall Street Zen downgraded it to 'sell'. The average analyst rating is 'Moderate Buy' with a target price of $21.00. Institutional investors have recently increased their stakes in the company, which focuses on developing radiopharmaceuticals for cancer treatment.

    Market Beat·
    US
    TLX
    +4.24%
    Market Beat·
    US
    TLX
    +4.24%

    12 Communication Services Stocks Moving In Wednesday's Pre-Market Session

    In Wednesday's pre-market session, Brag House Holdings (NASDAQ:TBH) saw a significant gain of 14.8%, reaching $0.47, while Teads Holding (NASDAQ:TEAD) rose by 7.93% to $0.68. Other gainers included Bilibili (NASDAQ:BILI) up 5.35% to $31.89, and Baidu (NASDAQ:BIDU) up 4.71% to $157.1. Conversely, SurgePays (NASDAQ:SURG) experienced the largest drop, falling 17.6% to $1.54. Netflix (NASDAQ:NFLX) shares decreased by 6.84% to $81.3 following Q4 earnings release.

    benzinga_article·
    US
    NFLW
    -2.34%
    US
    NFLU
    -3.87%
    US
    NFLX
    -2.13%
    benzinga_article·
    US
    NFLW
    -2.34%
    US
    NFLU
    -3.87%
    US
    NFLX
    -2.13%

    17:31 ET PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight

    The PSMA-targeted therapy market is projected to grow significantly by 2034, driven by rising prostate cancer diagnosis rates and an expanding pipeline of therapies. Key players like Lantheus and Telix Pharmaceuticals are developing novel treatments, with PLUVICTO achieving blockbuster status in 2024. The market is influenced by factors such as technological advancements in therapy and diagnostics, and the increasing incidence of prostate cancer among aging populations. Emerging therapies are expected to reshape the market landscape, enhancing treatment options for patients with prostate cancer.

    prnewswire·
    US
    TLX
    +4.24%
    prnewswire·
    US
    TLX
    +4.24%
    © 2026 Longbridge｜Disclaimer